Marketing-authorisation holder
Argenx B.V.
9 medicines in 4 countries, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder
9 medicines in 4 countries, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
9 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| VYVGART20 mg / ml · Solution | Efgartigimod alfa | Canada | Marketed | 2023 |
| VYVGART400mg · Injectable | Efgartigimod alfa | United States | Marketed | 2021 |
| VYVGARTSoluzione iniettabile in siringa pre-riempita | Efgartigimod alfa | Italy | Authorised | |
| VYVGART 1.000 MG SOLUCION INYECTABLE1000 mg · Solución inyectable | Efgartigimod alfa | Spain | Authorised | 2024 |
| VYVGART 1.000 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA1000 mg · Solución inyectable en jeringa precargada | Efgartigimod alfa | Spain | Marketed | 2025 |
| VYVGART 20 MG/ML CONCENTRADO PARA SOLUCIÓN PARA PERFUSIÓN20 mg/ml · Concentrado para solución para perfusión | Efgartigimod alfa | Spain | Marketed | 2022 |
| Vyvgart Hytrulo1,000mg/5ml;10,000units/5ml (200mg/2,000units/ml) · Injection | Efgartigimod alfa, Hyaluronidase | United States | Marketed | 2025 |
| VYVGART HYTRULO1008mg · Injectable | Efgartigimod alfa, Hyaluronidase | United States | Marketed | 2023 |
| VYVGART SC200 mg / ml · Solution | Efgartigimod alfa | Canada | Marketed | 2026 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 3 | 3 | 0 | CompaniesAll medicines |
| United States | 3 | 3 | 0 | CompaniesAll medicines |
| Canada | 2 | 2 | 0 | CompaniesAll medicines |
| Italy | 1 | 1 | 0 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.